单次大剂量高剂量率近距离放疗与两次及三次分割治疗局部晚期前列腺癌的比较
该研究比较了单次大剂量高剂量率近距离放疗(SD-HDR-BT)与两次或三次分割HDR-BT在中高危局限性前列腺癌中的疗效,中位随访10年。293例患者分三组接受1×19Gy或1×20Gy(A组49例)、2×13Gy(B组138例)、3×10.5Gy(C组106例)。10年生化无复发生存率分别为64%、72%、76%(p=0.2),总生存无显著差异。
要点
- 单次大剂量HDR-BT与2次或3次分割相比,10年生化无复发生存率无统计学显著差异(p=0.2)。
- 三组总生存无统计学显著差异。
- 多因素分析中风险分组和ADT使用是复发的显著预测因素(p=0.0003和0.03),剂量不是。
核心结论
- 长期结局数据显示,单次大剂量HDR-BT与2次或3次分割HDR-BT相比,PSA控制降低但无统计学显著差异,总生存无差异。
研究设计与样本
- 比较单次大剂量HDR-BT与两次或三次分割HDR-BT的疗效,中位随访10年,共293例中高危局限性前列腺癌患者。
- A组49例接受1×19Gy或1×20Gy,B组138例接受2×13Gy,C组106例接受3×10.5Gy HDR-BT。
- 主要终点为生化无复发生存间期(bRFI),晚期泌尿生殖(GU)和胃肠道(GI)毒性采用RTOG量表和国际前列腺症状评分(IPSS)评估。
主要发现
- 10年时Kaplan-Meier估计的bRFI为A组64%、B组72%、C组76%(p=0.2)。
- 总生存无统计学显著差异。
- 多因素分析中风险分组和ADT使用是复发的显著预测因素(p=0.0003和0.03),剂量不是。
- 10年时GU 3级事件为A组8%、B组2%、C组13%(p=0.01)。
- IPSS≥20为A组31%、B组20%、C组23%(p=0.6);GI 3级为A组和B组0%、C组2%(p=0.3);未观察到GU或GI 4级事件。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Single-dose high-dose-rate brachytherapy (SD-HDR-BT) was compared to two or three fraction HDR BT in intermediate and high-risk localized prostate cancer with median follow-up of 10 years. MATERIALS AND METHODS: 293 patients received 1 × 19Gy or 1 × 20Gy (Group A = 49), 2 × 13Gy (Group B = 138), or 3 × 10.5 Gy (Group C = 106) HDR BT. The primary endpoint was biochemical relapse-free interval (bRFI). Late genitourinary (GU) and gastrointestinal (GI) morbidity used RTOG scales and the International Prostate Symptom Score (IPSS). Freedom from biochemical relapse (bRFI), overall survival (OS) and GU, GI and IPSS morbidity were calculated using Kaplan-Meier (K-M) method and log-rank test. Univariate and multivariate hazard ratios (HR) were obtained using Cox's proportional hazard. RESULTS: At 10 years, K-M estimates of bRFI were 64 % (Group A), 72 % (Group B), and 76 % (Group C) (p = 0.2). No statistically significant difference was seen in OS. In multivariate analysis risk-category and ADT administration, but not dose, were significant predictors of relapse (p = 0.0003 and 0.03, respectively). At ten years, GU grade 3 events were 8 % (A), 2 % (B) and 13 % (C); (p = 0.01). IPSS ≥ 20 was 31 % (A), 20 % (B) and 23 % (C); (p = 0.6) and grade 3 GI was 0 % in groups A and B and 2 % in C; (p = 0.3). No GU or GI grade-4 events were observed. Pre-treatment IPSS was a highly significant predictor of failure in multivariate analysis. CONCLUSIONS: Long-term outcome data show reduced but not statistically significant difference in PSA control, and no difference in overall survival, between SD-HDR-BT and 2 or 3 fractions of HDR-BT.
引用
- Hoskin P, Rojas A, Ostler P, et al. Single-dose high-dose-rate brachytherapy versus two and three fractions for locally advanced prostate cancer. Radiother Oncol. 2024. PMID: 38997094. doi:10.1016/j.radonc.2024.110426
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。